Patents Assigned to Genentech
  • MODULATING LACTOGENIC ACTIVITY IN MAMMALIAN CELLS
    Publication number: 20210009988
    Abstract: The present disclosure relates to methods, cells and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interests, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have modulated lactogenic activity. The present disclosure also relates to methods and compositions for modulating pyruvate kinase muscle (PKM) expression (e.g., PKM-1 expression) in a mammalian cell to thereby reduce or eliminate the lactogenic activity of the cell, as well compositions comprising a cell having reduced or eliminated lactogenic activity and methods of using the same.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 14, 2021
    Applicant: GENENTECH, INC.
    Inventors: Shahram Misaghi, Masaru Ken Shiratori, Bradley Richard Snedecor, Michael W. Laird
  • BIOANALYTICAL ANALYSIS OF SITE-SPECIFIC ANTIBODY DRUG CONJUGATES
    Publication number: 20210011000
    Abstract: Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.
    Type: Application
    Filed: May 26, 2020
    Publication date: January 14, 2021
    Applicant: Genentech, Inc.
    Inventors: Martine Darwish, Surinder Kaur, Dian Su, Keyang Xu
  • THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210009599
    Abstract: Compounds of Formula (I): salts thereof and methods of making and use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 14, 2021
    Applicant: Genentech, Inc.
    Inventors: Mark Zak, Terry Kellar, Paul Gibbons
  • Anti-Ly6E antibodies and methods of use
    Patent number: 10889651
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: January 12, 2021
    Assignee: Genentech, Inc.
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20210002359
    Abstract: Variant immunoglobulins with one or more amino acid modifications in the Fe region that have increased in vivo half-lives, and methods of using the same are provided.
    Type: Application
    Filed: June 1, 2020
    Publication date: January 7, 2021
    Applicant: Genentech, Inc.
    Inventors: Henry B. LOWMAN, Yik Andy YEUNG, Lisa A. DAMICO, Napaleone FERRARA, Yu-Ju G. MENG
  • TARGETED INTEGRATION OF NUCLEIC ACIDS
    Publication number: 20210002669
    Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins, as well as methods of producing and using said TI host cells.
    Type: Application
    Filed: December 21, 2018
    Publication date: January 7, 2021
    Applicant: GENENTECH, INC.
    Inventors: Chi Kin Domingos Ng, Yongping Guo Crawford, Amy Shen, Meixia Zhou, Bradley R. Snedecor, Shahram Misaghi, Albert Eric Gao
  • Antibodies against BACE1 and use thereof for neural disease immunotherapy
    Patent number: 10882920
    Abstract: The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: January 5, 2021
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus
  • Host cell comprising nucleic acids encoding bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 and antibody production
    Patent number: 10882921
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: January 5, 2021
    Assignee: GENENTECH, INC.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Process for preparing BTK inhibitors
    Patent number: 10882864
    Abstract: Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3?-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4?]bipyridinyl-2?-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: January 5, 2021
    Assignee: Genentech, Inc.
    Inventors: Danial Beaudry, Theresa Cravillion, Francis Gosselin, Ngiap-Kie Lim, Sushant Malhotra, Qingping Tian, Haiming Zhang, Alexander Gmehling, Alec Fettes, Stephan Bachmann
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS
    Publication number: 20200405855
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.
    Type: Application
    Filed: February 7, 2020
    Publication date: December 31, 2020
    Applicant: Genentech, Inc.
    Inventors: Jane GROGAN, Yuanyuan XIAO, Patrick CAPLAZI, Steve LIANOGLOU, Jason HACKNEY, Eugene Yu-Chuan CHIANG
  • Anti-hypusine antibodies and uses thereof
    Patent number: 10877042
    Abstract: The invention provides anti-hypusine antibodies and their use in detecting and isolating polypeptides containing hypusine and/or deoxyhypusine, as well as compositions and kits comprising the anti-hypusine antibodies.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 29, 2020
    Assignee: Genentech, Inc.
    Inventors: Qianting Zhai, Paul J. Carter
  • Anti-PDL1 antibody formulations
    Patent number: 10875922
    Abstract: The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: December 29, 2020
    Assignee: Genentech, Inc.
    Inventors: Ying Yang, Sreedhara Alavattam
  • DIAGNOSTIC AND THERAPEUTIC METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA)
    Publication number: 20200399703
    Abstract: The present invention provides prognostic, predictive, and therapeutic methods for the treatment of rheumatoid arthritis (RA). The invention is based, at least in part, on the discovery that the expression level of one or more biomarkers described herein in a sample (e.g., a synovial tissue sample, a synovial fluid sample, or a combination thereof) from an individual having RA can be used in methods of determining whether an individual having RA is likely to exhibit disease progression, identifying an individual having RA who is likely to respond to a treatment including a disease modifying anti-rheumatic drug (DMARD), predicting responsiveness of an individual having RA to a treatment including a DMARD, selecting a therapy for an individual having RA, and treating an individual having RA, as well as related kits.
    Type: Application
    Filed: July 23, 2020
    Publication date: December 24, 2020
    Applicants: Genentech, Inc., Queen Mary University of London, Queen Mary University of London
    Inventors: Myles LEWIS, Costantino PITZALIS, Nandhini RAMAMOORTHI, Michael John TOWNSEND, Jason HACKNEY
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20200399244
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R—R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: May 28, 2020
    Publication date: December 24, 2020
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • POLYMORPHS AND SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND METHODS OF PRODUCTION
    Publication number: 20200399286
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Application
    Filed: May 15, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • Anti-NGF Antibodies for Treatment of Various Disorders
    Publication number: 20200399357
    Abstract: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including pain, asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.
    Type: Application
    Filed: May 11, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventor: David L. Shelton
  • PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF
    Publication number: 20200399275
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, Marian C. Bryan
  • METHODS OF TREATING ALZHEIMER'S DISEASE
    Publication number: 20200399352
    Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.
    Type: Application
    Filed: February 5, 2020
    Publication date: December 24, 2020
    Applicant: GENENTECH, INC.
    Inventors: William Cho, Michel Friesenhahn, Robert Paul, Michael Ward
  • TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF
    Publication number: 20200399274
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • METHODS OF PURIFYING POLYPEPTIDES
    Publication number: 20200399307
    Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.
    Type: Application
    Filed: January 22, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Hui F. LIU, Brian David KELLEY, Deanna E. MYERS, Beth MCCOOEY, Krista Marie PETTY